<DOC>
	<DOC>NCT02081118</DOC>
	<brief_summary>The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a month under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).</brief_summary>
	<brief_title>Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Ages eligible for study : 18 years to 74 years Genders eligible for study : Male and Female Diagnosed with T2DM Taking a stable dose of metformin monotherapy HbA1c levels of between ≥ 7.0% and ≤ 10.0% Females of childbearing potential who are not pregnant and agree to use a reliable method of birth control Written informed consent must be obtained Pregnant or nursing (lactating) women Diagnosis of type 1 diabetes mellitus Uncontrolled diabetes defined as a FPG level of &gt; 240 mg/dL at screening A significant change in body weight in the 3 months before screening Any history of GI intolerance Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC Known history of acute or chronic pancreatitis A history of alcohol or drug abuse or drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>